Impact through Publications

Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria

Efficacy and Cost-effectiveness of Dabigatran Etexilate versus Warfarin in Atrial Fibrillation (AF) in Different Age Subgroups: A United States Perspective

Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation - a pharmacokinetic justification

Ostreotide (somatostatin analogue) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus

The relaxant effect of xenin on rat ileum is mediated by apamin- sensitive neurotensin type receptors

A Model to Quantify the Influence of Treatment Patterns and Optimize Outcomes in nAMD

Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration

Effectiveness and safety of ranibizumab for the treatment of central retinal vein occlusion: results from the real-world global LUMINOUS study

Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data

Real -world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study

Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study

Differences in COPD exacerbation risk between women and men: analysis from the UK CPRD data

Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modeling approach

Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: The CRYSTAL open-label randomised trial

Enhanced Elimination of Dabigatran: Identifying the Appropriate Patient for the Use of Continuous VenoVenous HemoDialysis (CVVHD) Instead of Intermittent Hemodialysis (IHD)

Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat-Tail Bleeding Model

Effective elimination of dabigatran by haemodialysis

Comparable pharmacokinetics and pharmacodynamics in Japanese and Caucasian volunteers and patients after oral administration of dabigatran etexilate

Interpretation of point-of-care INR results in patients treated with dabigatran

Hypertension therapy in practice test. Calcium antagonist receives good marks.

Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate – results from an observational study in 9.672 patients

Current evidence on switching between biologic therapies for Still's disease: a systematic review

Secukinumab in Moderate-to-Severe Graves' Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

The modernisation of newborn screening as a pan-European challenge - An international delphi study

A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab

Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events

a post-hoc evaluation of data from the HAWK and HARRIER trials

A Systematic Review of Real-World Studies. Ophthalmology (Impact Factor 12

A Systematic Review of Real-World Studies

Does Real Time Artificial Intelligence (AI) Based Visual Pathology Enhancement of Three-Dimensional (3D) Optical Coherence Tomography (OCT) Scans Optimize Treatment Decision in nAMD Patients: Rationale and Design of the RAZORBILL Study

Treatment patterns and persistence rates with anti-VEGF treatment for diabetic macular edema in the UK: a real-world study

Residual Inflammatory Risk in Coronary Heart Disease – Incidence of Elevated High Sensitive CRP in a Real-world Cohort

Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database

Neovascular age-related macular degeneration – a visual acuity model of natural disease progression and ranibizumab treatment effect

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomized controlled study

Long term Evaluation of Dabigatran 150 versus 110 mg BID in Patients with Non-Valvular Atrial Fibrillation

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis

Thromboprophylaxis with Dabigatran after total hip arthroplasty in Indian patients: A sub-analysis of a double- blind, double-dummy, randomized RE-NOVATE II study

Pharmacokinetics and pharmacodynamics of dabigatran etexilate 75 mg BID in patients with severe chronic kidney disease - prospective validation of a post hoc determined dose

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: A cross over blinded randomized study (SPRING)

Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study

Prediction of Bleeding Events in Patients with Venous Thromboembolism on Stable Anticoagulation

Microvascular Outcomes in Type 2 Diabetes Patients Treated with vildagliptin vs. sulfonylurea: a Retrospective Study using German Electronic Medical Records

Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement

Comparison of Dabigatran Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial

Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery

Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 2 randomized trials

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes

Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database

Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

Pharmacometric Characterization of Dabigatran Hemodialysis

Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects

Dabigatran Etexilate in Atrial Fibrillation Patients with Severe Renal Impairment – Dose Identification using Pharmacokinetic Modeling and Simulation

Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery

Quality of INR control and outcomes following venous thromboembolism

Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis controlled trials

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada

Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis

Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four phase III trials

Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: risk of bleeding

Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after hip or knee replacement: pooled analysis of the RE MOBILIZE, RE-MODEL and RE-NOVATE trials

Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate

Warfarin in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement

Prognostic value of codon 918 (ATG—>ACG) RET-Proto-oncogene mutations in sporadic medullary thyroid carcinoma

Expression and distribution of the prolactin receptor in normal rat liver and in experimental liver cirrhosis

Duct changes and K-ras mutations in disease-free pancreas: analysis of type, age relation and spatial distribution

Human Galanin modulates human colonic motility in vitro. Characterization of structural requirements

Pituitary adenylate cyclase-activating peptide is a potent modulator of human colonic motility

PACAP is a stimulator of neurogenic contraction in guinea pig ileum

Pituitary adenylate cyclase activating polypeptide (PACAP) is a potent relaxant of the rat ileum

Vasoactive intestinal polypeptide induces neurogenic contraction of guinea-pig ileum. Involvement of acetylcholine and substance P

Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide